Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PTPN22 | Q9Y2R2 | 11/20 | 0.43 |
| ▸ | OXTR | P30559 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 6/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | PTPN12 | Q05209 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211219 | 0.83 | RAB9A (0.43) | LMNATP53 | |
| SCHEMBL5583388 | 0.82 | LMNA (0.45) | LMNATP53PIM1PIM2 | |
| SCHEMBL5600184 | 0.72 | TP53 (0.55) | LMNATP53PTPN22PIM1PIM2 | |
| SCHEMBL6177556 | 0.68 | PIM1 (0.51) | LMNATP53PTPN22PIM1PIM2 | |
| SCHEMBL210033 | 0.67 | HDAC1 (0.47) | TP53 | |
| SCHEMBL29527237 | 0.65 | KDM4E (0.66) | LMNATP53PIM1 | |
| SCHEMBL335319 | 0.65 | KDM4E (0.66) | LMNATP53PIM1 | |
| SCHEMBL4805124 | 0.65 | GAA (0.38) | — | |
| Methylene Chloride SCHEMBL28849518 | 0.65 | LMNA (0.62) | LMNATP53PIM1 | |
| Hydrochloric Acid SCHEMBL11498190 | 0.64 | KDM4E (0.64) | LMNATP53PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | LMNA 1962/4885TP53 86/4885PTPN22 3421/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | LMNA 1851/4885TP53 115/4885PTPN22 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.